A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

"IPN01194 will be taken orally over a period of 28 days (a Cycle) at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1).~Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision."

"All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I.~Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision"